{'fraction_non_alphanumeric': 0.06030150753768844, 'fraction_numerical': 0.02512562814070352, 'mean_word_length': 4.387387387387387, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease

Transthyretin (TTR) binds Abeta and may reduce brain Abeta, a key pathogenetic feature in Alzheimer's disease (AD). N‐3 fatty acids (FA), i.e. DHA and EPA, increase TTR transcription in rat brain. We studied the effects of n‐3 FAs on plasma TTR levels in patients with AD. Methods: 204 outpatients with AD were randomised to DHA/EPA (80/20%), 4 g/d during 6 mo (EPAX, Pronova AS) or placebo (n‐6 FA). After 6 mo all patients received EPAX for another 6 mo. Cognitive function was assessed by MMSE and ADASCog.